Evidence map›Paper›PMID 34280415›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2021

Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates.

Alireza Hassani Najafabadi, Zeynab Izadi Najaf Abadi, Marisa E Aikins, Kathryn E Foulds, Mitzi M Donaldson, Wenmin Yuan, Emeka B Okeke, Jutaek Nam, Yao Xu, Priyan Weerappuli and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 38 citations in OpenAlex.

  1. Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Alireza Hassani NajafabadiDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT 06030, USA.
Zeynab Izadi Najaf AbadiDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Marisa E AikinsDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Kathryn E FouldsThe Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mitzi M DonaldsonThe Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wenmin YuanDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Emeka B OkekeDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biology, State University of New York, Fredonia, NY 14063, USA.
Jutaek NamDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.
Yao XuDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Priyan WeerappuliBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Taryn HetrickUnit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
David AdamsBiomedical Research Core Facilities, University of Michigan, Ann Arbor, MI 48109, USA.
Patrick A LesterUnit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Andres M SalazarOncovir, Inc., Washington, DC 20008, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Anna SchwendemanDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Robert A SederThe Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
James J MoonDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.. Electronic address: moonjj@med.umich.edu.
University of Michigan–Ann Arbor · USNational Institutes of Health · USBeth Israel Deaconess Medical Center · USBioSurfaces (United States) · USNational Institute of Allergy and Infectious Diseases · USOncovir (United States) · USSUNY Fredonia · USUConn Health · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Non-Human Primate CoreZICAI005103 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FOULDS, KATHRYN · 2009 to 2025
$22.7M
KLF14 and Cardiovascular DiseaseR01HL134569 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHEN, YUQING EUGENE · 2017 to 2024
$5.3M
New Engineering Strategy for Harnessing Immune System against Head and Neck CancerR01DE030691 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEI, YU LEO, MOON, JAMES J. · 2021 to 2025
$2.9M
Novel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6M
Novel biomaterials for IBD treatmentR01DK125087 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAMADA, NOBUHIKO, MOON, JAMES J. · 2020 to 2023
$2.5M
Elicitation of mucosal immune responses against HIVR01AI127070 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2020
$2.3M
Nanomaterials for eliciting anti-tumor T-cells-Diversity SupplementR01CA210273 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2017 to 2021
$2.2M
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiformeR01EB022563 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2019
$1.7M
HDL-Loaded Nanoparticles for Glioma TherapeuticsR21NS091555 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2016
$427k
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA210273NHLBI NIH HHS R01 HL134569NIAID NIH HHS HHSN272201300006CNIAID NIH HHS R01 AI127070NIBIB NIH HHS R01 EB022563NIDCR NIH HHS R01 DE030691NIDDK NIH HHS R01 DK125087NINDS NIH HHS R01 NS122536NINDS NIH HHS R21 NS091555
6 · The paper itself

Abstract

Conventional cancer vaccines based on soluble vaccines and traditional adjuvants have produced suboptimal therapeutic efficacy in clinical trials. Thus, there is an urgent need for vaccine technologies that can generate potent T cell responses with strong anti-tumor efficacy. We have previously reported the development of synthetic high-density protein (sHDL) nanodiscs for efficient lymph node (LN)-targeted co-delivery of antigen peptides and CpG oligonucleotides (a Toll-like receptor-9 agonist). Here, we performed a comparative study in mice and non-human primates (NHPs) to identify an ideal vaccine platform for induction of CD8+ T cell responses. In particular, we compared the efficacy of CpG class B, CpG class C, and polyICLC (a synthetic double-stranded RNA analog, a TLR-3 agonist), each formulated with antigen-carrying sHDL nanodiscs. Here, we report that sHDL-Ag admixed with polyICLC elicited robust Ag-specific CD8+ T cell responses in mice, and when used in combination with α-PD-1 immune checkpoint inhibitor, sHDL-Ag + polyICLC eliminated large established (~100 mm

Indexed as

Cancer VaccinesCD8-Positive T-LymphocytesAdjuvants, ImmunologicAnimalsMacaca mulattaMiceVaccines, SyntheticAdjuvants, ImmunologicCancer VaccinesVaccines, Syntheticadjuvantcancer immunotherapynanoparticleTLR agonistvaccine

Identifiers

PMID34280415
PMCPMC8440392
OpenAlexW3187005873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.